Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist.
A retrospective analysis of 104 women with leiomyomata uteri treated with LA for at least 12 weeks demonstrated a negative correlation between the percent reduction in uterine volume and serum E2 concentration at treatment week 12. The patient's age, height, or pretreatment uterine volume were not correlated with the degree of uterine shrinkage.
Friedman
A J
AJ
Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts 02115.
Daly
M
M
Juneau-Norcross
M
M
Rein
M S
MS
D000328:Adult; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D016729:Leuprolide / Q000627:therapeutic use*; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D014599:Uterus / Q000473:pathology*
D004958:Estradiol; D016729:Leuprolide